银屑病性别差异的研究进展

doi:10.35541/cjd.20230200

中华皮肤科杂志 ›› 2024, e20230200.doi: 10.35541/cjd.20230200

银屑病性别差异的研究进展

魏露¹ 王畅² 张步鑫³ 徐俊涛³ 王丽³ 王庆兴³ 陆玲玲³ 刘爱民³

¹河南中医药大学第二临床医学院，郑州 450053；²湖南中医药大学第二附属医院皮肤科，长沙 410005；³河南省中医院（河南中医药大学第二附属医院）皮肤科，郑州 450053

收稿日期:2023-04-12 修回日期:2024-05-14 发布日期:2024-09-24
通讯作者: 刘爱民 E-mail:13592603226@163.com
基金资助:
国家自然科学基金（81874471）；河南省高等学校重点研究项目（24A360010）；河南省中医药文化著作出版专项（TCMCB2022013）；河南中药科研专项（2024ZY3051、2022ZY1085、2024ZY1014、2024ZY3055、20-21ZY2053）；河南中医药大学2023年研究生科研创新能力提升计划项目（2023KYCX049）

Gender differences in psoriasis

Wei Lu¹, Wang Chang², Zhang Buxin³, Xu Juntao³, Wang Li³, Wang Qingxing³, Lu Lingling³, Liu Aimin³

¹The Second Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450053, China; ²Department of Dermatology, the Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410005, China; ³Department of Dermatology, Henan Provincial Hospital of Traditional Chinese Medicine （the Second Affiliated Hospital of Henan University of Chinese Medicine）, Zhengzhou 450053, China

Received:2023-04-12 Revised:2024-05-14 Published:2024-09-24
Contact: Liu Aimin E-mail:13592603226@163.com
Supported by:
National Natural Science Foundation of China （81874471）; Key Research Project for Higher Education Institutions in Henan Province （24A360010）; Henan Province Traditional Chinese Medicine Cultural Works Publishing Project （TCMCB2022013）; Henan Traditional Chinese Medicine Research Project （2024ZY3051, 2022ZY1085, 2024ZY1014, 2024ZY3055, 20-21ZY2053）; Graduate Research Innovation Ability Enhancement Program Project of Henan University of Chinese Medicine in 2023 （2023KYCX049）

摘要/Abstract

摘要： 【摘要】疾病的患病率、严重程度、治疗反应、预后等可能具有性别偏差。近年研究显示，银屑病的发生发展、治疗、疾病负担、预后及共病等方面具有性别差异，这为提高银屑病的治疗反应、改善预后提供了新的方向。本文综述银屑病在流行病学、临床特征、治疗、疾病负担、预后及共病等方面的性别差异。

关键词: 银屑病, 性别差异, 疾病严重程度, 预后, 长期管理

Abstract: 【Abstract】 The prevalence, severity, treatment response, and prognosis of diseases may have gender biases. In recent years, studies have shown that there are gender differences in the occurrence, development, treatment, disease burden, prognosis, and comorbidities of psoriasis, which provides new directions for improving the treatment response and prognosis of psoriasis. This review summarizes the gender differences in epidemiology, clinical characteristics, treatment, disease burden, prognosis, and comorbidities of psoriasis.

Key words: Psoriasis, Gender differences, Severity of illness, Long term management, Prognosis

魏露王畅张步鑫徐俊涛王丽王庆兴陆玲玲刘爱民. 银屑病性别差异的研究进展[J]. 中华皮肤科杂志, 2024,e20230200. doi:10.35541/cjd.20230200

Wei Lu, Wang Chang, Zhang Buxin, Xu Juntao, Wang Li, Wang Qingxing, Lu Lingling, Liu Aimin. Gender differences in psoriasis[J]. Chinese Journal of Dermatology,2024,e20230200. doi:10.35541/cjd.20230200

参考文献 59

［1］	Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans［J］. Hum Reprod Update, 2005,11（4）:411⁃423. doi: 10.1093/humupd/dmi008.
［2］	王澍, 王明悦, 夏杨, 等. 6093例银屑病患者临床资料回顾性分析［J］. 中国医学前沿杂志（电子版）, 2021,13（12）:1⁃8. doi: 10.12037/YXQY.2021.12⁃01.
［3］	Patel S, Yang K, Nambudiri VE. Exploring sex differences in generalized pustular psoriasis hospitalizations［J］. Exp Dermatol, 2023,32（8）:1312⁃1313. doi: 10.1111/exd.14742.
［4］	Grellmann C, Dombrowsky W, Fabricius V, et al. Epidemiology and treatment of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in Germany: a real⁃world evidence study［J］. Adv Ther, 2021,38（1）:366⁃385. doi: 10.1007/s12325⁃020⁃01522⁃8.
［5］	Pina Vegas L, Sbidian E, Penso L, et al. Epidemiologic study of patients with psoriatic arthritis in a real⁃world analysis: a cohort study of the French health insurance database［J］. Rheumatology （Oxford）, 2021,60（3）:1243⁃1251. doi: 10.1093/rheumatology/keaa448.
［6］	Karmacharya P, Crowson CS, Bekele D, et al. The epidemiology of psoriatic arthritis over five decades: a population⁃based study［J］. Arthritis Rheumatol, 2021,73（10）:1878⁃1885. doi: 10.1002/art.41741.
［7］	Parisi R, Iskandar I, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study［J］. BMJ, 2020,369:m1590. doi: 10.1136/bmj.m1590.
［8］	Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States［J］. JAMA Dermatol, 2021,157（8）:940⁃946. doi: 10.1001/jamadermatol.2021.2007.
［9］	Asili P, Tootoonchi N, Nasimi M, et al. Demographic aspects, clinical characteristics, and therapeutic approaches in geriatric psoriasis: A study from a tertiary center［J］. Dermatol Ther, 2022,35（8）:e15628. doi: 10.1111/dth.15628.
［10］	Golińska J, Sar⁃Pomian M, Rudnicka L. Dermoscopy of plaque psoriasis differs with plaque location, its duration, and patient's sex［J］. Skin Res Technol, 2021,27（2）:217⁃226. doi: 10.1111/srt.12933.
［11］	Murer C, Sgier D, Mettler SK, et al. Gender differences in psoriasis: a Swiss online psoriasis survey［J］. Arch Dermatol Res, 2021,313（2）:89⁃94. doi: 10.1007/s00403⁃020⁃02066⁃1.
［12］	Chen K, Wang G, Jin H, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients［J］. Oncotarget, 2017,8（28）:46381⁃46389. doi: 10.18632/oncotarget. 18453.
［13］	Eder L, Thavaneswaran A, Chandran V, et al. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis［J］. Ann Rheum Dis, 2013,72（4）:578⁃582. doi: 10.1136/annrheumdis⁃2012⁃201357.
［14］	Furer V, Wollman J, Levartovsky D, et al. Sex⁃based differences in sonographic and clinical findings among patients with psoriatic arthritis［J］. J Rheumatol, 2023,50（2）:197⁃203. doi: 10.3899/jrheum.220547.
［15］	Na SJ, Jo SJ, Youn JI. Clinical study on psoriasis patients for past 30 years （1982-2012） in Seoul National University Hospital Psoriasis Clinic［J］. J Dermatol, 2013,40（9）:731⁃735. doi: 10.1111/1346⁃8138.12224.
［16］	Odorici G, Paganelli A, Peccerillo F, et al. Moderate to severe psoriasis: a single⁃center analysis of gender prevalence［J］. Ital J Dermatol Venerol, 2021,156（2）:226⁃230. doi: 10.23736/S2784⁃8671.18.06200⁃4.
［17］	Hägg D, Sundström A, Eriksson M, et al. Severity of psoriasis differs between men and women: a study of the clinical outcome measure psoriasis area and severity index （pasi） in 5438 Swedish register patients［J］. Am J Clin Dermatol, 2017,18（4）:583⁃590. doi: 10.1007/s40257⁃017⁃0274⁃0.
［18］	Napolitano M, Mastroeni S, Fania L, et al. Sex⁃ and gender⁃associated clinical and psychosocial characteristics of patients with psoriasis［J］. Clin Exp Dermatol, 2020,45（6）:705⁃711. doi: 10.1111/ced.14218.
［19］	Peng C, Xu X, Chen W, et al. Epidemiological variations in the global burden of psoriasis, an analysis with trends from 1990 to 2017［J］. Front Med （Lausanne）, 2021,8:585634. doi: 10.3389/fmed.2021.585634.
［20］	Colombo D, Bianchi L, Fabbrocini G, et al. The CANOVA study real⁃world evidence of biologic treatments in moderate⁃severe psoriasis in Italy: a gender perspective［J］. Womens Health Rep （New Rochelle）, 2022,3（1）:450⁃457. doi: 10.1089/whr.2021. 0124.
［21］	Maul JT, Augustin M, Sorbe C, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two⁃country, multicentre, prospective, noninterventional registry study［J］. Br J Dermatol, 2021,185（6）:1160⁃1168. doi: 10.1111/bjd.20387.
［22］	Cao F, He YS, Wang Y, et al. Global burden and cross⁃country inequalities in autoimmune diseases from 1990 to 2019［J］. Autoimmun Rev, 2023,22（6）:103326. doi: 10.1016/j.autrev. 2023.103326.
［23］	Duruöz MT, Gezer HH, Nas K, et al. Gender⁃related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: a multi⁃center study［J］. Joint Bone Spine, 2021,88（4）:105177. doi: 10.1016/j.jbspin.2021.105177.
［24］	Lubrano E, Scriffignano S, Fatica M, et al. Psoriatic arthritis in males and females: differences and similarities［J］. Rheumatol Ther, 2023,10（3）:589⁃599. doi: 10.1007/s40744⁃023⁃00535⁃3.
［25］	Passia E, Vis M, Coates LC, et al. Sex⁃specific differences and how to handle them in early psoriatic arthritis［J］. Arthritis Res Ther, 2022,24（1）:22. doi: 10.1186/s13075⁃021⁃02680⁃y.
［26］	Nas K, Kiliç E, Tekeoğlu İ, et al. The effect of gender on disease activity and clinical characteristics in patients with axial psoriatic arthritis［J］. Mod Rheumatol, 2021,31（4）:869⁃874. doi: 10.1080/14397595.2020.1812870.
［27］	Gossec L, Walsh JA, Michaud K, et al. Women with psoriatic arthritis experience higher disease burden than men: findings from a real⁃world survey in the United States and Europe［J］. J Rheumatol, 2023,50（2）:192⁃196. doi: 10.3899/jrheum.220154.
［28］	Alamri A, Alqahtani R, Alshareef I, et al. Psoriasis in Saudi population: gender differences in clinical characteristics and quality of life［J］. Cureus, 2022,14（3）:e22892. doi: 10.7759/cureus.22892.
［29］	Orbai AM, Perin J, Gorlier C, et al. Determinants of patient⁃reported psoriatic arthritis impact of disease: an analysis of the association with sex in 458 patients from fourteen countries［J］. Arthritis Care Res （Hoboken）, 2020,72（12）:1772⁃1779. doi: 10.1002/acr.24090.
［30］	Maul JT, Navarini AA, Sommer R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis ⁃ a lesson for practice［J］. J Eur Acad Dermatol Venereol, 2019,33（4）:700⁃708. doi: 10.1111/jdv.15324.
［31］	Marques E, Paluch Z, Boháč P, et al. Epidemiology of moderate⁃to⁃severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents［J］. J Dermatolog Treat, 2022,33（3）:1435⁃1448. doi: 10.1080/09546634.2020.1826393.
［32］	Hernández⁃Fernández CP, Carretero G, Rivera R, et al. Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort［J］. Acta Derm Venereol, 2021,101（1）:adv00354. doi: 10.2340/00015555⁃3711.
［33］	Mease PJ, Gladman DD, Merola JF, et al. Potential impact of sex and BMI on response to therapy in psoriatic arthritis: post hoc analysis of results from the SEAM⁃PsA trial［J］. J Rheumatol, 2022,49（8）:885⁃893. doi: 10.3899/jrheum.211037.
［34］	Han L, Guo M, Wang B, et al. Sex⁃differential downregulation of methotrexate on plasma viscosity and whole blood viscosity in psoriasis［J］. Clin Hemorheol Microcirc, 2022,81（4）:305⁃314. doi: 10.3233/CH⁃211343.
［35］	Landgren AJ, Jonsson CA, Bilberg A, et al. Sex differences in cytokines and adipokines in obese patients with PsA and controls undergoing a weight loss intervention［J］. RMD Open, 2024,10（1）:e003821. doi: 10.1136/rmdopen⁃2023⁃003821.
［36］	Hägg D, Eriksson M, Sundström A, et al. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men［J］. PLoS One, 2013,8（5）:e63619. doi: 10.1371/journal.pone.0063619.
［37］	Verardi F, Maul LV, Borsky K, et al. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry （SDNTT）［J］. J Eur Acad Dermatol Venereol, 2024,38（4）:719⁃731. doi: 10.1111/jdv.19730.
［38］	Kojanova M, Fialova J, Cetkovska P, et al. Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex⁃specific differences in psoriasis in the Czech Republic［J］. Dermatol Ther, 2021,34（2）:e14849. doi: 10.1111/dth.14849.
［39］	Di Cesare A, Bianchi C, Pescitelli L, et al. Risk of acute infections in psoriatic patients during biologic therapies is linked to gender［J］. J Eur Acad Dermatol Venereol, 2019,33（10）:e362⁃e364. doi: 10.1111/jdv.15658.
［40］	van der Schoot LS, van den Reek J, Groenewoud J, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side⁃effects than male patients: results from the prospective BioCAPTURE registry［J］. J Eur Acad Dermatol Venereol, 2019,33（10）:1913⁃1920. doi: 10.1111/jdv.15733.
［41］	Sondermann W, Djeudeu Deudjui DA, Körber A, et al. Psoriasis, cardiovascular risk factors and metabolic disorders: sex⁃specific findings of a population⁃based study［J］. J Eur Acad Dermatol Venereol, 2020,34（4）:779⁃786. doi: 10.1111/jdv.16029.
［42］	Zheng Q, Kuai L, Jiang W, et al. Clinical feature, lifestyle behavior and non⁃communicable diseases comorbidities among psoriasis patients in Shanghai: gender disparity analysis based on a cross⁃sectional study［J］. Clin Cosmet Investig Dermatol, 2022,15:2751⁃2762. doi: 10.2147/CCID.S393697.
［43］	Duvetorp A, Mrowietz U, Nilsson M, et al. Sex and age influence the associated risk of depression in patients with psoriasis: a retrospective population study based on diagnosis and drug⁃use［J］. Dermatology, 2021,237（4）:595⁃602. doi: 10.1159/00050 9732.
［44］	Mulder M, Wenink MH, Vriezekolk JE. Being overweight is associated with not reaching low disease activity in women but not men with psoriatic arthritis［J］. Rheumatology （Oxford）, 2022,61（2）:770⁃774. doi: 10.1093/rheumatology/keab338.
［45］	Loo WY, Tee YC, Han WH, et al. Predictive factors of psoriatic arthritis in a diverse population with psoriasis［J］. J Int Med Res, 2024,52（1）:30006052 31221014. doi: 10.1177/0300060523122 1014.
［46］	Haddad A, Saliba W, Lavi I, et al. The association of psoriatic arthritis with all⁃cause mortality and leading causes of death in psoriatic arthritis［J］. J Rheumatol, 2022,49（2）:165⁃170. doi: 10.3899/jrheum.210159.
［47］	Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum［J］. Arch Dermatol, 2005,141（5）:601⁃606. doi: 10.1001/archderm.141.5.601.
［48］	Sobolev V, Soboleva A, Denisova E, et al. Differential expression of estrogen⁃responsive genes in women with psoriasis［J］. J Pers Med, 2021,11（9）:925. doi: 10.3390/jpm11090925.
［49］	Gegenhuber B, Wu MV, Bronstein R, et al. Gene regulation by gonadal hormone receptors underlies brain sex differences［J］. Nature, 2022,606（7912）:153⁃159. doi:10.1038/s41586⁃022⁃04686⁃1.
［50］	Adachi A, Honda T, Egawa G, et al. Estradiol suppresses psoriatic inflammation in mice by regulating neutrophil and macrophage functions［J］. J Allergy Clin Immunol, 2022,150（4）:909⁃919.e8. doi: 10.1016/j.jaci.2022.03.028.
［51］	Iwano R, Iwashita N, Takagi Y, et al. Estrogen receptor α activation aggravates imiquimod⁃induced psoriasis⁃like dermatitis in mice by enhancing dendritic cell interleukin⁃23 secretion［J］. J Appl Toxicol, 2020,40（10）:1353⁃1361. doi: 10. 1002/jat.3988.
［52］	Kanda N, Watanabe S. 17beta⁃estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression［J］. J Invest Dermatol, 2004,123（2）:319⁃328. doi: 10.1111/j.0022⁃202X.2004.12645.x.
［53］	Wu H, Zeng L, Ou J, et al. Estrogen acts through estrogen receptor⁃β to promote mannan⁃induced psoriasis⁃like skin inflammation［J］. Front Immunol, 2022,13:818173. doi: 10.3389/fimmu.2022.818173.
［54］	杨梅, 唐彩红, 桂雨晴, 等. 咪喹莫特诱导银屑病模型小鼠T细胞免疫功能改变与性别的关系［J］. 中国药理学通报, 2022,38（4）:589⁃597. doi: 10.12360/CPB202108021.
［55］	Kobayashi K, Chikazawa S, Chen Y, et al. Oestrogen inhibits psoriasis⁃like dermatitis induced by imiquimod in mice in relation to increased IL⁃10 producing cells despite elevated expression of IL⁃22, IL⁃23, IL⁃17 mRNA［J］. Exp Dermatol, 2023,32（2）:203⁃209. doi: 10.1111/exd.14688.
［56］	Singh RP, Hahn BH, Bischoff DS. Interferon genes are influenced by 17β⁃estradiol in SLE［J］. Front Immunol, 2021,12:725325. doi: 10.3389/fimmu.2021.725325.
［57］	Gudjónsson JE, Kárason A, Antonsdóttir AA, et al. HLA⁃Cw6⁃positive and HLA⁃Cw6⁃negative patients with psoriasis vulgaris have distinct clinical features［J］. J Invest Dermatol, 2002,118（2）:362⁃365. doi: 10.1046/j.0022⁃202x.2001.01656.x.
［58］	Hong J, Qu Z, Ji X, et al. Genetic associations between IL⁃6 and the development of autoimmune arthritis are gender⁃specific［J］. Front Immunol, 2021,12:707617. doi: 10.3389/fimmu.2021.70 7617.
［59］	He S, Yang F, Lu C, et al. Sex⁃specific differences in patients with psoriatic arthritis:a nationwide study from the Chinese Registry of Psoriatic Arthritis （CREPAR IV）［J］. Clin Rheumatol, 2024,43（3）:1063⁃1071. doi: 10.1007/s10067⁃023⁃06859⁃3.

[1]	陈嘉琪张禁唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 84-88.
[2]	吴曹英杨永婷王春申耀元贾卉卉李婷婷赵娟康晓静. 老年黑色素瘤临床病理特征及预后分析[J]. 中华皮肤科杂志, 2025, 58(1): 40-46.
[3]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[4]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.
[5]	张聪聪邵雪宝张莹宋昊王小坡张韡徐秀莲姜祎群曾学思孙建方臧洁陈浩. ALK、TRK及ROS1在Spitz肿瘤中的表达及与临床和组织病理学特征的关系[J]. 中华皮肤科杂志, 2024, 57(9): 807-814.
[6]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[7]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 765-769.
[8]	窦进法王建波张帅李建国刘鸿伟张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 57(8): 739-742.
[9]	隋长霖常晓赵琪朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574.
[10]	张元文孙从乾潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024, 57(5): 471-475.
[11]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[12]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[13]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[14]	徐教生伏利兵徐哲徐子刚. 皮下脂膜炎样T细胞淋巴瘤研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230172-e0230172.
[15]	叶慧薛如君张锡宝. 生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220795-e20220795.

银屑病性别差异的研究进展

Gender differences in psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 59

相关文章 15

Metrics

本文评价

推荐阅读 10